home / stock / lexxw / lexxw news

LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 08/11/22

Stock Information
Company Name: Lexaria Bioscience Corp. Warrant
Stock Symbol: LEXXW
Market: NASDAQ
Website: lexariabioscience.com
Menu
LEXXW LEXXW Quote LEXXW Short LEXXW News LEXXW Articles LEXXW Message Board
Get LEXXW Alerts

News, Short Squeeze, Breakout and More Instantly...
LEXXW - Lexaria Discusses Valuation Metrics for Biotech Industry

(TheNewswire) Third Party Analysis for Biotech and Pharma Industries Kelowna, British Columbia – TheNewswire - August 11, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a glob...
LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its receipt of a positive full written response from the Food and Drug Administration (“FDA”) from its pre-Investigational New Drug (“Pre-IND”) meeting regar...

LEXXW - Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension

(TheNewswire) Significant Milestone Achieved in Commercial Product Development Program Abbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA Pathway Kelowna, British Columbia – TheNewswire - August 10, 2022 – Lexaria B...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. Accordin...
LEXXW - Lexarias DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 27, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce th...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its exclusive* Japanese licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand ...

LEXXW - Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 26, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce th...
LEXXW - Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing

(TheNewswire) Kelowna, British Columbia – TheNewswire - July 14, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is please...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery techno...

LEXXW - Lexarias Human Nicotine Study Nearing Start Date

(TheNewswire) Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. Kelowna, British Columbia – TheNewswire - July 13, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Na...
Previous 10 Next 10